

December 22, 2020

Cagent Vascular, LLC Carol Burns CEO 150 Strafford Avenue #315 Wayne, Pennsylvania 19087

Re: K203437

Trade/Device Name: Serranator PTA Serration Balloon Catheter

Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter

Regulatory Class: Class II Product Code: PNO

Dated: November 20, 2020 Received: November 23, 2020

Dear Carol Burns:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

K203437 - Carol Burns Page 2

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/training-and-continuing-education/cdrh-learn) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Gregory O'Connell
Assistant Director
DHT2C: Division of Coronary
and Peripheral Intervention Devices
OHT2: Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

K203437
Device Name Serranator® PTA Serration Balloon Catheter
Indications for Use (Describe) The Serranator® PTA Serration Balloon Catheter is intended for dilatation of lesions in infrapopliteal arteries. Not for use in the coronary or neuro-vasculature.
Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



510(k) Summary

[as required by 21 CFR 807.92(c)]

Serranator® PTA Serration Balloon Catheter 510(k) K203437

DATE PREPARED:	November 20, 2020		
APPLICANT:	Carol Burns/ President & CEO		
	150 Strafford Avenue, #315		
	Wayne, PA 19087		
CONTACT:	Carol A. Burns, President and CEO		
	Phone: (610) 688-2006		
	Fax: (610) 688-2667		
	Email: cburns@cagentvascular.com		
TRADE NAME:	Serranator® PTA Serration Balloon Catheter		
COMMON NAME:	Percutaneous Catheter		
CLASSIFICATION	21CFR 870.1250		
REGULATION:			
DEVICE CLASS:	Class II		
PANEL CODE:	PNO		
PREDICATE DEVICE:	K193181		

INTENDED USE/INDICATIONS FOR USE:

The Serranator® PTA Serration Balloon Catheter is intended for dilatation of lesions in infrapopliteal arteries. Not for use in the coronary or neuro-vasculature.

DEVICE DESCRIPTION:

The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications as described in the Indication for Use statement. The Serranator® has a nylon semi-compliant balloon with three embedded external metal strips or scoring elements. The unique scoring elements are serrated, designed to modify the plaque by creating linear, interrupted scoring along the endoluminal surface. This occurs during balloon inflation and is designed to aid arterial expansion.

Cagent Vascular, LLC

COMPARISON WITH PREDICATE DEVICE:

Comparison of the subject device (Serranator) and the predicate device (Serranator, K193181) show that the technological characteristics of the subject device such as components, design, sterilization method, shelf life and operating principle are identical or similar to the currently marketed predicate device.

The intended use/indications for use between the subject device and the predicate device are identical.

Cagent Vascular, LLC 2

COMPARISON WITH PREDICATE DEVICE:

	Subject Device	Predicate Device
Device Name	Serranator® PTA Serration	
	Balloon Catheter	Same
Manufacturer	Cagent Vascular, LLC	
510(k)	-	K193181
Intended Use/Indication for Use	The Serranator® PTA	
	Serration Balloon	
	Catheter is intended for	
	dilatation of lesions in	
	infrapopliteal arteries.	
	Not for use in the	
	coronary or neuro-	
	vasculature.	
Regulation	21CFR870.1250	Same
Regulation Name	Percutaneous catheter	
Regulation Class	Class 2	
Product Code	PNO	
Prescription/OTC	Prescription	
Catheter Design	OTW	
Balloon diameter (mm)	2.5, 3.0, 3.5	
Balloon length (mm)	40, 80, 120	
Effective Length (cm)	150	
Balloon Compliance	Semi Compliant	
Sterilization Method	Ethylene Oxide Gas	
Nominal Pressure (atm)	6	
Rated Burst Pressure (atm)	12	
Dispenser	Yes (unchanged)	
Pouch	Yes (unchanged)	

Cagent Vascular, LLC

NON-CLINICAL TESTING/PERFORMANCE DATA:

Non-clinical bench testing was performed on the subject device to determine substantial equivalence. The following tests were performed:

- Catheter Delivery, Deployment and Retraction
- Balloon Fatigue
- Catheter Torsion
- Catheter Flex/Kink
- Catheter Tensile Test

In vitro bench testing demonstrated that the subject device performed as intended.

BIOCOMPATIBILITY:

Biocompatibility testing was not repeated for the subject device as there were no new materials and no manufacturing process changes as compared to the predicate device.

The subject device meets all acceptance criteria and is biocompatible.

CONCLUSION:

The Serranator® PTA Serration Balloon Catheter included in this notification is substantially equivalent to the previously cleared predicate device in terms of intended use and technological characteristics as demonstrated by bench testing.